Cite
HARVARD Citation
Bianchini, G. et al. (2017). Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer. Breast cancer research. 19 (1), pp. 1-12. [Online].